Premalignant Cervical Disease and Delayed HPV Vaccination CAROLANN

  • Slides: 29
Download presentation
Premalignant Cervical Disease and Delayed HPV Vaccination CAROLANN RISLEY, MSN, WHNP, KIM GEISINGER, MD

Premalignant Cervical Disease and Delayed HPV Vaccination CAROLANN RISLEY, MSN, WHNP, KIM GEISINGER, MD UNIVERSITY OF MISSISSIPPI MEDICAL CENTER

Purpose Describe the number of women under 21 who were diagnosed with premalignant cervical

Purpose Describe the number of women under 21 who were diagnosed with premalignant cervical cancer and correlate their history of vaccination.

What is the Problem? HPV causes cancer. HPV vaccination is grossly underutilized. Mississippi Lowest

What is the Problem? HPV causes cancer. HPV vaccination is grossly underutilized. Mississippi Lowest BUT - highest rate of cervical cancer deaths. rate of HPV Vaccination. – MS has highest vaccination rates for all other vaccines.

“ Lack of provider recommendation is reported as the most likely cause of the

“ Lack of provider recommendation is reported as the most likely cause of the low uptake of the vaccine. CENTER FOR DISEASE CONTROL AND PREVENTION ”

Pap smear screening decreased Consensus guidelines – 2012 American Cancer Society, pathology organizations ASCCP

Pap smear screening decreased Consensus guidelines – 2012 American Cancer Society, pathology organizations ASCCP ACOG – American College of Obstetrics and Gynecologists US Preventative Task Force HPV disease typically grows slowly 5 -10 years HPV genotype prevalence younger - clear

When to start screening Paps – Age? U. S. Preventive Services Task Force (USPSTF)

When to start screening Paps – Age? U. S. Preventive Services Task Force (USPSTF) Age 21. Recommend against screening women aged under 21. “A” recommendation American College of Obstetricians and Gynecologists (ACOG) Age 21 Regardless of the age of onset of sexual activity. “A” recommendation

Who, Where, When – Sample N=179 Retrospective Who - Females age 14 – 20

Who, Where, When – Sample N=179 Retrospective Who - Females age 14 – 20 Where When What Why Analysis – 15, 201 records – USA, Mississippi State Health Department – Between 2011 -2014 – 4 years – High grade Pap Test Results – Moderate, Severe – vaccinated or not?

Data Analysis Total paps – 15, 508 done (14 – 20 YOA) Total abnormal

Data Analysis Total paps – 15, 508 done (14 – 20 YOA) Total abnormal high grade paps – 179 – 1% F/U Biopsy done Total biopsy done w results – 110 – 62% High grade From 110 bx = 62% potential to progress to cancer.

Age at Abnormal Pap Smear

Age at Abnormal Pap Smear

Sample with HPV vaccine HPV 1 Dose – 28. 5% No HPV 0 Dose

Sample with HPV vaccine HPV 1 Dose – 28. 5% No HPV 0 Dose – 58. 7%

Sample - HPV Shot vs No HPV Shot Frequency Yes Had HPV 1 shot

Sample - HPV Shot vs No HPV Shot Frequency Yes Had HPV 1 shot Percent 51 28. 5 105 58. 7 No record 23 12. 8 Total 179 100. 0 No HPV shot given

HPV vaccination given late vs early Using age the current CDC guidelines HPV vaccination

HPV vaccination given late vs early Using age the current CDC guidelines HPV vaccination recommended HPV 9 -12 years old, Only 1 of the 179 females in sample were vaccinated between 9 -12 Mean age – 16 shot given

Age at HPV Shot 1

Age at HPV Shot 1

Take Home Point – Too late Mean age at 1 st HPV shot –

Take Home Point – Too late Mean age at 1 st HPV shot – 16, potential already exposed to virus Lower immune response Only 1 out of 179 females with premalignant cervical cancer received the HPV shot at recommended age 12

Other significance in this data Race and abnormal pap smears and biopsy Even though

Other significance in this data Race and abnormal pap smears and biopsy Even though White to Black had even number of abn paps the degree of biopsy severity – higher in black. – Disparity Mortality 2014 Blacks 3 x more likely Whites ICC

Pearson chi square = 12. 166 df = 2 p = 0. 002 Black

Pearson chi square = 12. 166 df = 2 p = 0. 002 Black Females were significantly more likely to receive the HPV vaccine than White Females. Vaccine Hesitancy?

Missed Opportunities prior to Disease Onset 37 prior vaccine visits T dap Meningococcal Varicella

Missed Opportunities prior to Disease Onset 37 prior vaccine visits T dap Meningococcal Varicella 53 Doses 32 Doses 38 Doses

Software / Clinic prompts MIIX State Data base – immunizations DOES NOT have HPV

Software / Clinic prompts MIIX State Data base – immunizations DOES NOT have HPV listed in the Vaccination View that prompts the nurse to offer the vaccine, For example, Tdap, Hep B, etc. All listed The RN must manually input HPV on this table in this sample.

Clinical questions – Future implications? 1. Should we adjust screening guidelines for females if

Clinical questions – Future implications? 1. Should we adjust screening guidelines for females if they have not been vaccinated at age 9 -12 2. Data shows increase in abnormal high grade paps at age 17 3. Should we adjust screening guidelines for race ? 4. P U S H HPV Vaccination

Joke Q: What's the best kind of cancer? A: The one you don't get.

Joke Q: What's the best kind of cancer? A: The one you don't get. #HPV vaccine is #cancer prevention! #2 shots 2 stop. Cancer

END OF Slides Remaining slides for my information.

END OF Slides Remaining slides for my information.

Consensus Guidelines based Clinical Trial - ATHENA Trial and ALTs Trial Clinical trials –

Consensus Guidelines based Clinical Trial - ATHENA Trial and ALTs Trial Clinical trials – science sound, but stats debated, can we generalize to our population. Genomics – generalize to the individual and that individual cohort. Age – “Cervical Cancer rare in adolescents and young women” –Schiffman, M, Castle, P. 2007. Lancet HPV and Cervical Cancer

Persistent HPV high-grade Causes Cancer Concern Causes lasts more than 6 months action in

Persistent HPV high-grade Causes Cancer Concern Causes lasts more than 6 months action in clinical world

Question Did anyone in the most severe cin 3 or cis have hpv vaccine?

Question Did anyone in the most severe cin 3 or cis have hpv vaccine?